The combination of the canonical mTOR inhibitor, everolimus, with intensive hyper-CVAD chemotherapy produced a CR rate of 25% in a diverse population of R/R B-ALL and T-ALL patients; the median OS was about 6 months [151]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.